Weekly insulin injections: a breakthrough for diabetics!
Weekly insulin injections: a breakthrough for diabetics!
In recent years, a lot has moved in the therapy of diabetes, especially in the area of insulin treatment. Especially for people with type 2 diabetes, a new approach, the weekly long-term insulin, could make a noticeable difference. According to a report by Entry into basal insulin therapy.
The idea behind it is simple: through weekly doses, patients can adapt their insulin doses more efficiently. In a study with EFSitora, a newly developed weekly insulin, it has been shown that it is not only safe, but also lowers the HBA1C value as well as conventional therapy with daily insulin injections. This could be an enormous relief for many affected people who often fight with daily insulin.
long -term insulin in focus
Long-term insulins enjoy great importance in the therapy of type 1 and type 2 diabetes. Currently used insulin have some advantages, but also have their weaknesses, which require ongoing research on new insulins. According to diabetes anker , the development of a weekly insulin is a promising step. Traditionally, long-term insulins are injected once or twice a day, which is a challenge for many patients.
modern insulins have a flat active curve and no pronounced effective peaks, which is helpful in practice. Nevertheless, less than 30% of the insulin treated people are able to achieve an HBA1C value of less than 7%, which shows that there is a need to catch up. Over 90% of those affected want to achieve a more stable metabolism in their illness without having to put the daily insulin for the foreground. Here a weekly administration could really make the difference by increasing the loyalty to therapy by up to 35%.
future of insulin therapy
The search for innovative approaches in insulin therapy is in full swing. News under the banner of research are, for example, nasal insulins or those that work directly in the liver. However, the prerequisites for the success of a weekly long -term insulin include a secure profile of action and avoiding hypoglycaemia. Insulin Icodec from Novo Nordisk, which is recently under development, shows potential in this regard because it has an extended half -life and therefore allows weekly injections.
The German Diabetes Society continuously campaigns for the update of medical guidelines to ensure high-quality treatment for all diabetic. These regular updates create a framework that not only standardizes diagnostics and classification, but also the therapy and care of diabetes patients.
In summary, it can be said that the weekly long -term insulin and further developments in insulin therapy arouse great hopes - not only for the patients, but also for the treating doctors who work more efficiently and more patient -friendly therapy.| Details | |
|---|---|
| Ort | Waren (Müritz), Deutschland |
| Quellen | |
Kommentare (0)